CLARIVATE PLC
Clarivate provides intelligence solutions, workflow software and technology-enabled services to customers in academia and government, intellectual property, and life sciences and healthcare. Its customers include academic institutions and libraries, research organizations, corporations, law firms, government entities, and pharmaceutical, biotechnology, and medical device companies. Clarivate is headquartered in London, United Kingdom. Clarivate operates through three segments. Academia & Government offers research and learning products and services, including Web of Science, ProQuest, Alma, Vega and Polaris. Intellectual Property provides patent and trademark services, data and software, including Derwent, CompuMark, IPfolio and FoundationIP. Life Sciences & Healthcare offers research and development, commercial and medtech intelligence, including the Cortellis product suite. Clarivate earns money primarily through subscriptions and recurring contracts, including patent and trademark renewal services, as well as transactional sales of content, consulting and professional services.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $CLVT in the last 7 days.
No SEC Form 4 filings for $CLVT in the last 30 days.
See all $CLVT insider activity →William Blair downgraded Clarivate Analytics (NASDAQ:CCC) to 'Market Perform' after the company agreed to a $7.75 per share take-private deal, valuing it at $6.1 billion. The stock, trading at $7.62, has risen 16% since the announcement. Analysts see limited upside potential. The deal is expected to close in Q1 2027.
Altaris completed the acquisition of Clarivate's Life Sciences & Healthcare business. Latham & Watkins advised the financing sources. Clarivate plc (CLVT) is the publicly traded company involved.
Wandercraft acquired Ekso Bionics to form a global medical exoskeleton company. Automation Anywhere agreed to buy Boost.ai for conversational AI. Beam Global will acquire ScoutDI for $24M to expand drone tech. Altaris completed a $600M deal for Clarivate's healthcare business.
Recent CLVT coverage spans corporate actions, mergers & acquisitions and financial news.
The downgrade and deal announcement are likely to weigh on the stock.
The divestiture removes a non-core segment, potentially improving focus on core analytics business.
Clarivate’s life‑sciences unit is now owned by Altaris, removing it from the public company.
Executive departure may raise uncertainty about the Life Sciences & Healthcare segment.
The divestiture removes a revenue stream but provides cash to lower leverage, likely causing modest short‑term price pressure while improving long‑term balance‑sheet strength.
AlphAI scores every news story that mentions CLVT with an AI model for sentiment and relevance, and aggregates insider trades from CLARIVATE PLC's SEC EDGAR Form 4 filings. Figures refresh continuously.
William Blair downgraded Clarivate Analytics (NASDAQ:CCC) to 'Market Perform' after the company agreed to a $7.75 per share take-private deal, valuing it at $6.1 billion. The stock, trading at $7.62, has risen 16% since the announcement. Analysts see limited upside potential. The deal is expected to close in Q1 2027.
2 min readAltaris completed the acquisition of Clarivate's Life Sciences & Healthcare business. Latham & Watkins advised the financing sources. Clarivate plc (CLVT) is the publicly traded company involved.
1 min readWandercraft acquired Ekso Bionics to form a global medical exoskeleton company. Automation Anywhere agreed to buy Boost.ai for conversational AI. Beam Global will acquire ScoutDI for $24M to expand drone tech. Altaris completed a $600M deal for Clarivate's healthcare business.
2 min readClarivate's Henry Levy, President of Life Sciences & Healthcare, terminated employment. A separation agreement includes retention payments and benefits. Details were disclosed in an SEC filing.
1 min readClarivate (NYSE: CLVT) completed the $600M sale of its Life Sciences & Healthcare segment to Altaris, simplifying its portfolio and focusing on Academia & Government and Intellectual Property segments. The company plans to use proceeds to reduce debt and strengthen its balance sheet, aiming to drive growth and shareholder value. Clarivate will update its full-year 2026 guidance on November 3, 2026.
2 min readCLARIVATE PLC (CLVT) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Clarivate Announces Final Results of Offer to Purchase for Cash Certain of its Outstanding Debt Securities LONDON, September 24, 2026: Clarivate Plc (NYSE: CLVT) ("Clarivate"), a leading global provider of transformative intelligence, today announced the expiration a
2 min readClarivate Plc (NYSE: CLVT) announced the pricing terms for its cash tender offer to purchase up to $75M of its 3.875% Senior Secured Notes due 2028, with a proration mechanism in place. The offer, managed by Citigroup, expires on September 23, 2026, with a settlement date expected on September 25, 2026.
2 min readCLARIVATE PLC (CLVT) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Clarivate Announces Pricing Terms of Offer to Purchase for Cash Certain of its Outstanding Debt Securities LONDON, September 23, 2026: Clarivate Plc (NYSE: CLVT) ("Clarivate"), a leading global provider of transformative intelligence, today announced the Reference Yi
2 min readClarivate Plc (NYSE: CLVT) announced it will release its Q3 2026 financial results on November 3, 2026, before market open. The company will host a conference call and webcast at 8:30 AM ET to discuss the results, with details available on its investor website.
1 min readClarivate Plc (NYSE: CLVT) announced a cash tender offer to purchase up to $75M of its 3.875% Senior Secured Notes due 2028. The offer, managed by Citigroup, expires on September 23, 2026, with a settlement date of September 25, 2026. The total consideration is based on a fixed spread and reference yield, with accrued interest also payable.
2 min read
